Skip to main content
Susan Perlman, MD, Neurology, Los Angeles, CA, Ronald Reagan UCLA Medical Center

SusanLeePerlmanMD

Neurology Los Angeles, CA

Movement Disorder, Neurodegenerative, Neurodevelopmental Disabilities

Professor, Neurology, UCLA School of Medicine

Dr. Perlman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Perlman's full profile

Already have an account?

  • Office

    UCLA Medical Center
    300 Medical Plaza, Suite B 200
    Los Angeles, CA 90095
    Phone+1 310-794-1195
    Fax+1 310-794-1195
  • Is this information wrong?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1976 - 1979
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1975 - 1976
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 1975

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1976 - 2024
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Skyclarys (Omaveloxolone) Becomes the First FDA-Approved Treatment for Friedreich’s Ataxia
    Skyclarys (Omaveloxolone) Becomes the First FDA-Approved Treatment for Friedreich’s AtaxiaMarch 10th, 2023
  • FDA Approves Skyclarys
    FDA Approves SkyclarysJanuary 3rd, 2023
  • Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
    Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressDecember 8th, 2022
  • Join now to see all

Hospital Affiliations